openPR Logo
Press release

Investigation announced for Investors in Mylan N.V. (NASDAQ: MYL) over potential Wrongdoing

10-02-2020 11:50 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Mylan N.V. (NASDAQ: MYL) shares over possible breaches of fiduciary duty.

An investigation on behalf of investors in Mylan N.V. (NASDAQ: MYL) shares over possible breaches of fiduciary duty.

An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Mylan N.V.

Investors who are current long term investors in Mylan N.V. (NASDAQ: MYL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for investors in Mylan N.V. (NASDAQ: MYL stocks follows a lawsuit filed against Mylan N.V. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: MYL stocks, concerns whether certain Mylan N.V. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Western District of Pennsylvania the plaintiff alleges that the defendants violated Federal Securities Laws. More specifically, the claims against Mylan N.V. arise from the Company's misrepresentations and omissions regarding rampant abuses of federal quality control regulations, including at the Morgantown facility.

The plaintiff says that under a scheme implemented by Mylan's President, Rajiv Malik, Mylan chemists manipulated quality control test data in order to create the facade that Mylan's drugs had achieved passing quality control results. In November 2016, a whistleblower reported Mylan's conduct to the U.S. Food & Drug Administration ("FDA").

The plaintiff claims that the truth began to be revealed on June 27, 2018, when Mylan N.V. revealed that the FDA had investigated the Morgantown plant in the Spring of 2018—the second FDA investigation of that plant in less than two years. According to the FDA, the Morgantown plant exhibited "significant deficiencies in [its] cleaning process[es]," "numerous instances of a lack of oversight," and "multiple instances" of Mylan chemists re-cleaning and re-swabbing quality control testing machines "multiple times until passing results were obtained."

The plaintiff says that as a result of these violations, Mylan N.V. was ultimately forced to reveal that it would be dramatically "restructuring" its Morgantown facility, including by terminating hundreds of employees, and reported a surprise quarterly loss on May 7, 2019, which the Company attributed, in part, to the Morgantown "restructuring." The disclosures concerning Mylan's misconduct and its impact on the Company's business and financial condition caused the value of Mylan stock to decline dramatically, resulting in significant damages to investors.

Those who purchased shares of Mylan N.V. (NASDAQ: MYL) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Mylan N.V. (NASDAQ: MYL) over potential Wrongdoing here

News-ID: 2148753 • Views:

More Releases from Shareholders Foundation

ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly NASDAQ: SINA)
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made. If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: FLR) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp. (NYSE: SOC)
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp. Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc. (NASDAQ: LNTH)
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Mylan

Anastrozole Tablets Market is Booming Worldwide - Teva Pharmaceuticals, Mylan
Anastrozole Tablets Market Insights The anastrozole tablets market is estimated to be valued at US$ 278.1 million in 2020 and is expected to exhibit a CAGR of 2.8% over the forecast period (2020-2027). Coherent Market Insights has published a new comprehensive analysis on the Anastrozole Tablets Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This report highlights essential metrics including market size, revenue forecasts, CAGR, adoption trends, and regulatory
Cystinosis Market: Epidemiology, Therapies, Companies, DelveInsight | Horizon Ph …
Cystinosis emerging therapies, such as NPI-001, and others, are expected to boost the Cystinosis Market in the upcoming years. DelveInsight has launched a new report on "Cystinosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cystinosis, historical and forecasted epidemiology as well as the Cystinosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover about the Cystinosis market
Oxycodone Market is Booming Worldwide | Pfizer, Apotex, Mylan
The Latest Released Oxycodone market study has evaluated the future growth potential of Global Oxycodone market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision-makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, and emerging trends along with essential drivers, challenges, opportunities,
Scabies Treatment Market is Thriving Worldwide | Apotex, Mylan, Bayer
The Latest published market study on Global Scabies Treatment Market provides an overview of the current market dynamics in the Scabies Treatment, as well as what our survey respondents all outsourcing decision-makers predict the market will look like in 2032. The study breaks the market by revenue and volume (wherever applicable) and price history to estimate the size and trend analysis and identify gaps and opportunities. Some of the players
Cabozantinib Market Is Booming Worldwide with Exelixis, Mylan, Sandoz
HTF MI introduces new research on Cabozantinib covering the micro level of analysis by competitors and key business segments (2023-2029). The Cabozantinib explores a comprehensive study of various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing. Some of the major key players profiled in the
Global Ambroxol Industry Chain Research Report2022|Bayer, Novartis, Mylan
QY Research has recently published a new report, titled Global Ambroxol Market Report, History and Forecast 2014-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Ambroxol market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the